Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Fulltext:
307607.pdf
Embargo:
until further notice
Size:
1.468Mb
Format:
PDF
Description:
Publisher’s version
Publication year
2024Source
Blood, 143, 22, (2024), pp. 2227-2244ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Haematology
Journal title
Blood
Volume
vol. 143
Issue
iss. 22
Page start
p. 2227
Page end
p. 2244
Subject
Haematology - Radboud University Medical CenterAbstract
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly because patients with CMML are mostly older and comorbid. Therefore, the decision between a nonintensive treatment approach and allo-HCT represents a delicate balance, especially because prospective randomized studies are lacking and retrospective data in the literature are conflicting. International consensus on the selection of patients and the ideal timing of allo-HCT, specifically in CMML, could not be reached in international recommendations published 6 years ago. Since then, new, CMML-specific data have been published. The European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee assembled a panel of experts in the field to provide the first best practice recommendations on the role of allo-HCT specifically in CMML. Recommendations were based on the results of an international survey, a comprehensive review of the literature, and expert opinions on the subject, after structured discussion and circulation of recommendations. Algorithms for patient selection, timing of allo-HCT during the course of the disease, pretransplant strategies, allo-HCT modality, as well as posttransplant management for patients with CMML were outlined. The keynote message is, that once a patient has been identified as a transplant candidate, upfront transplantation without prior disease-modifying treatment is preferred to maximize chances of reaching allo-HCT whenever possible, irrespective of bone marrow blast counts.
This item appears in the following Collection(s)
- Electronic publications [132359]
- Non RU Publications [15966]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.